Diagnostic usefulness of selected proteases and acute phase factors in patients with colorectal adenocarcinoma.
Acute phase factor
Acute phase reactants
Cathepsin B
Colorectal adenocarcinoma
Colorectal cancer
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Oct 2021
21 Oct 2021
Historique:
received:
07
04
2021
revised:
07
07
2021
accepted:
02
09
2021
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
12
11
2021
Statut:
ppublish
Résumé
Uncontrolled growth and loss of control over basic metabolic functions, leading to invasive proliferation and metastases, are the salient traits of malignant tumors in general and colorectal cancer in particular. Invasion and metastases hinder effective tumor treatment. While surgical techniques and radiotherapy can be used to remove tumor focus, only chemotherapy can eliminate dispersed neoplastic cells. However, the efficacy of the latter method is limited in the advanced stages of the disease. Therefore, recognition of the mechanisms involved in neoplastic cell spreading is indispensable for developing effective therapies. To use a number of biomarkers involved in cancer progression and identify a panel that could be used for effective early diagnosis. We recruited 185 patients with colorectal adenocarcinoma (98 men, 87 women with median age 63). Thirty-five healthy controls were sex and age-matched. Dukes' staging was as follows: A = 22, B = 52, C = 72, D = 39. We analyzed patients' blood serum before surgery. We determined: (1) Cathepsin B (CB) with Barrett's method (fluorogenic substrate); (2) Leukocytic elastase (LE) in a complex with alpha 1 trypsin inhibitor (AAT) using the immunoenzymatic MERCK test; (3) Total sialic acid (TSA) with the colorimetric periodate-resorcinol method; (4) Lipid-bound sialic acid (LASA) with the colorimetric Taut's method; and (5) The antitrypsin activity (ATA) employing the colorimetric test. In patients, the values of the five biochemical parameters were as follows: CB = 16.1 ± 8.8 mU/L, LE = 875 ± 598 µg/L, TSA = 99 ± 31 mg%, LASA = 0.68 ± 0.33 mg%, and ATA = 3211 ± 1504 U/mL. Except for LASA, they were significantly greater than those of controls: CB = 11.4 ± 6.5 mU/L, LE = 379 ± 187 µg/L, TSA = 71.4 ± 15.1 mg%, LASA = 0.69 ± 0.28 mg%, and ATA = 2016 ± 690 U/mL. For CB and LASA, the differences between the four Dukes' stages and controls were not statistically significant. The inter-stage differences for CB and LASA were also absent. The receiver operating characteristic (ROC) analysis revealed the potential diagnostic value of CB, TSA, and ATA. The area under ROC, sensitivity, and specificity for these three parameters were: 0.85, 72%, 90%; 0.75, 66%, 77%; and 0.77, 63%, 84%, respectively. The sensitivity and specificity for the three-parameter panel CB-TSA-ATA were equal to 88.2% and 100%, respectively. The increased value of CB, TSA, and ATA parameters are associated with tumor biology, invasion, and metastasis of colorectal cancer. The presented evidence suggests the potential value of the CB-TSA-ATA biochemical marker panel in early diagnostics.
Sections du résumé
BACKGROUND
BACKGROUND
Uncontrolled growth and loss of control over basic metabolic functions, leading to invasive proliferation and metastases, are the salient traits of malignant tumors in general and colorectal cancer in particular. Invasion and metastases hinder effective tumor treatment. While surgical techniques and radiotherapy can be used to remove tumor focus, only chemotherapy can eliminate dispersed neoplastic cells. However, the efficacy of the latter method is limited in the advanced stages of the disease. Therefore, recognition of the mechanisms involved in neoplastic cell spreading is indispensable for developing effective therapies.
AIM
OBJECTIVE
To use a number of biomarkers involved in cancer progression and identify a panel that could be used for effective early diagnosis.
METHODS
METHODS
We recruited 185 patients with colorectal adenocarcinoma (98 men, 87 women with median age 63). Thirty-five healthy controls were sex and age-matched. Dukes' staging was as follows: A = 22, B = 52, C = 72, D = 39. We analyzed patients' blood serum before surgery. We determined: (1) Cathepsin B (CB) with Barrett's method (fluorogenic substrate); (2) Leukocytic elastase (LE) in a complex with alpha 1 trypsin inhibitor (AAT) using the immunoenzymatic MERCK test; (3) Total sialic acid (TSA) with the colorimetric periodate-resorcinol method; (4) Lipid-bound sialic acid (LASA) with the colorimetric Taut's method; and (5) The antitrypsin activity (ATA) employing the colorimetric test.
RESULTS
RESULTS
In patients, the values of the five biochemical parameters were as follows: CB = 16.1 ± 8.8 mU/L, LE = 875 ± 598 µg/L, TSA = 99 ± 31 mg%, LASA = 0.68 ± 0.33 mg%, and ATA = 3211 ± 1504 U/mL. Except for LASA, they were significantly greater than those of controls: CB = 11.4 ± 6.5 mU/L, LE = 379 ± 187 µg/L, TSA = 71.4 ± 15.1 mg%, LASA = 0.69 ± 0.28 mg%, and ATA = 2016 ± 690 U/mL. For CB and LASA, the differences between the four Dukes' stages and controls were not statistically significant. The inter-stage differences for CB and LASA were also absent. The receiver operating characteristic (ROC) analysis revealed the potential diagnostic value of CB, TSA, and ATA. The area under ROC, sensitivity, and specificity for these three parameters were: 0.85, 72%, 90%; 0.75, 66%, 77%; and 0.77, 63%, 84%, respectively. The sensitivity and specificity for the three-parameter panel CB-TSA-ATA were equal to 88.2% and 100%, respectively.
CONCLUSION
CONCLUSIONS
The increased value of CB, TSA, and ATA parameters are associated with tumor biology, invasion, and metastasis of colorectal cancer. The presented evidence suggests the potential value of the CB-TSA-ATA biochemical marker panel in early diagnostics.
Identifiants
pubmed: 34754160
doi: 10.3748/wjg.v27.i39.6673
pmc: PMC8554409
doi:
Substances chimiques
Biomarkers, Tumor
0
Peptide Hydrolases
EC 3.4.-
Cathepsin B
EC 3.4.22.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6673-6688Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Med Invest. 2005 Feb;52(1-2):1-9
pubmed: 15751268
World J Gastroenterol. 2014 Oct 7;20(37):13246-57
pubmed: 25309062
Tumour Biol. 1992;13(3):121-32
pubmed: 1626178
An Med Interna. 2003 Oct;20(10):521-5
pubmed: 14585038
Mol Oncol. 2012 Aug;6(4):405-17
pubmed: 22507634
J Exp Ther Oncol. 2006;5(3):223-9
pubmed: 16528972
Biol Chem Hoppe Seyler. 1993 Dec;374(12):1135-46
pubmed: 8129860
Ann N Y Acad Sci. 1991;624:81-6
pubmed: 1905897
Lab Invest. 2007 Sep;87(9):851-7
pubmed: 17632542
Hum Pathol. 1999 Jun;30(6):680-6
pubmed: 10374777
Clin Cancer Res. 1998 Jun;4(6):1511-6
pubmed: 9626470
World J Gastroenterol. 2005 Jul 21;11(27):4225-9
pubmed: 16015694
Biol Chem Hoppe Seyler. 1996 May;377(5):301-11
pubmed: 8828821
J Pathol. 1985 Apr;145(4):307-14
pubmed: 3889245
BMC Cancer. 2008 Jul 10;8:194
pubmed: 18616803
Biochim Biophys Acta. 2008 Mar;1780(3):532-7
pubmed: 18023981
J Biol Chem. 1971 Jan 25;246(2):430-5
pubmed: 5542012
Rev Esp Oncol. 1981;28(4):591-641 contd
pubmed: 6764960
Int J Cancer. 1991 Sep 30;49(3):341-6
pubmed: 1917131
Pathol Oncol Res. 2020 Apr;26(2):1165-1173
pubmed: 31183614
Ann Clin Lab Sci. 2003 Spring;33(2):156-9
pubmed: 12817619
Int J Biol Markers. 2004 Jan-Mar;19(1):38-45
pubmed: 15077925
J Natl Cancer Inst. 1988 Oct 19;80(16):1333-7
pubmed: 3172258
J Physiol Biochem. 1998 Mar;54(1):9-13
pubmed: 9732103
Eur J Cancer. 1997 Nov;33(13):2216-20
pubmed: 9470809
Cancer Lett. 1995 Sep 25;96(2):267-75
pubmed: 7585467
Eur J Clin Invest. 1999 May;29(5):413-25
pubmed: 10354198
Cancer. 1990 May 1;65(9):2055-7
pubmed: 1695546
Curr Opin Hematol. 2011 Jan;18(1):19-24
pubmed: 21042214
Anticancer Res. 1997 Mar-Apr;17(2B):1249-53
pubmed: 9137482
Br J Cancer. 2006 Jun 19;94(12):1898-905
pubmed: 16755300
Cancer Lett. 2004 Mar 8;205(1):97-106
pubmed: 15036666
Int J Biol Markers. 1995 Jul-Sep;10(3):174-9
pubmed: 8551061
Clin Chem. 1976 Oct;22(10):1754-5
pubmed: 10097
Biochem J. 1980 Jun 1;187(3):909-12
pubmed: 6897924
Eur J Biochem. 1995 Oct 15;233(2):607-17
pubmed: 7588808
Biol Chem. 2004 Feb;385(2):145-52
pubmed: 15101557
Oncotarget. 2014 Jan 30;5(2):473-80
pubmed: 24457622
Cancer Res. 2004 Jul 1;64(13):4498-505
pubmed: 15231659
J Histochem Cytochem. 2004 May;52(5):629-40
pubmed: 15100240
Eur J Cancer. 2004 Jul;40(10):1610-6
pubmed: 15196548
J Immunol. 2007 May 1;178(9):5871-8
pubmed: 17442971
Adv Exp Med Biol. 1988;240:23-31
pubmed: 3266707
Eur J Biochem. 2004 Jan;271(2):281-90
pubmed: 14717696
Nutr Cancer. 2005;53(2):169-76
pubmed: 16573378
Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(3):157-65
pubmed: 2570482
Pol Merkur Lekarski. 2001 Jan;10(55):65-70
pubmed: 11320558
Clin Chim Acta. 2000 Feb 15;291(2):171-87
pubmed: 10675722
Am J Pathol. 1994 Aug;145(2):301-9
pubmed: 7519824
Orv Hetil. 1999 Aug 15;140(33):1833-6
pubmed: 10489782
Adv Exp Med Biol. 1996;389:281-94
pubmed: 8861022
Biomed Biochim Acta. 1991;50(4-6):531-40
pubmed: 1801719
Orv Hetil. 1996 Jul 28;137(30):1637-41
pubmed: 9019701
Hepatogastroenterology. 2007 Jan-Feb;54(73):53-7
pubmed: 17419230
Pol Merkur Lekarski. 2005 Aug;19(110):237-41
pubmed: 16245443
Biol Chem. 2001 May;382(5):805-10
pubmed: 11517934
Ann Ital Chir. 2020;91:649-647
pubmed: 33554943
Lancet Oncol. 2004 Mar;5(3):182-90
pubmed: 15003202
Trends Mol Med. 2008 Aug;14(8):351-60
pubmed: 18606570
Surg Oncol. 2006 Dec;15(4):217-22
pubmed: 17320378
Nihon Rinsho. 2005 Apr;63 Suppl 4:81-7
pubmed: 15861638
Postepy Biochem. 1988;34(1-2):23-46
pubmed: 3064060
Int Surg. 1996 Apr-Jun;81(2):136-9
pubmed: 8912078
J Histochem Cytochem. 1998 Jun;46(6):745-51
pubmed: 9603786
Neoplasma. 1985;32(1):51-4
pubmed: 3982561
J Pathol. 2007 Jun;212(2):152-60
pubmed: 17455170
Srp Arh Celok Lek. 1994 Nov-Dec;122(11-12):311-3
pubmed: 17974404
FEBS Lett. 1988 Feb 29;229(1):157-60
pubmed: 3162216
PLoS One. 2013;8(1):e51810
pubmed: 23300952
Cancer Res. 1982 Dec;42(12):5270-5
pubmed: 7139630
Cancer Res. 1989 Jul 15;49(14):3809-14
pubmed: 2544258
Cancer Res. 2006 Mar 15;66(6):2937-45
pubmed: 16540641
J Surg Res. 2000 Dec;94(2):153-8
pubmed: 11104655
Jpn J Clin Oncol. 2001 Dec;31(12):584-8
pubmed: 11902488
Cancer. 1988 Sep 15;62(6):1188-93
pubmed: 3261623
J Biol Chem. 1988 May 25;263(15):7364-9
pubmed: 3366785
Glycoconj J. 2018 Apr;35(2):139-160
pubmed: 29680984
Cancer Lett. 1997 Jan 30;112(2):155-60
pubmed: 9066722
Clin Exp Immunol. 1995 Feb;99(2):143-7
pubmed: 7531626
Neoplasma. 2004;51(1):38-43
pubmed: 15004658
J Immunol. 2005 Sep 1;175(5):3329-38
pubmed: 16116225